Aura Biosciences, Inc. Logo

Aura Biosciences, Inc.

Developing virus-like therapies to selectively destroy solid tumors in ocular & urologic oncology.

AURA | US

Overview

Corporate Details

ISIN(s):
US05153U1079
LEI:
Country:
United States of America
Address:
80 GUEST STREET, 2135 BOSTON
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Aura Biosciences, Inc. is a clinical-stage biotechnology company developing a novel class of targeted cancer therapies. The company's proprietary Virus-Like Drug Conjugate (VDC) platform uses Virus-Like Particles (VLPs) to selectively target and destroy solid tumor cells while aiming to preserve healthy tissue. Aura's initial focus is on indications with significant unmet medical needs, particularly in ocular and urologic oncology. Its lead clinical program is being evaluated as a potential first-line treatment for early-stage choroidal melanoma, a rare eye cancer where current treatments often result in vision loss.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Aura Biosciences, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Aura Biosciences, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Aura Biosciences, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Shuttle Pharmaceuticals Holdings, Inc. Logo
Develops drugs to enhance radiation therapy for cancer and offers predictive diagnostics.
United States of America SHPH
Siegfried Holding AG Logo
Global CDMO providing development and manufacturing of APIs and finished drugs for the pharma industry.
Switzerland SFZN
SIGA TECHNOLOGIES INC Logo
Develops antiviral drugs for global health security against biothreats and infectious diseases.
United States of America SIGA
Silexion Therapeutics Corp Logo
Developing a local drug delivery platform to treat KRAS-driven cancers and solid tumors.
United States of America SLXN
Develops oncolytic viruses and immunotherapeutics to destroy difficult-to-treat cancer cells.
South Korea 215600
Silo Pharma, Inc. Logo
Develops novel psychedelic & traditional therapies for pain and central nervous system disorders.
United States of America SILO
SINOVAC BIOTECH LTD Logo
Biopharmaceutical firm developing vaccines against infectious diseases like COVID-19 and Hepatitis.
United States of America SVA
Sionna Therapeutics, Inc. Logo
Developing novel NBD1 stabilizers and CFTR modulators to treat cystic fibrosis.
United States of America SION
SK biopharmaceuticals Co., Ltd. Logo
Develops and commercializes CNS and oncology therapies for global markets, focusing on the U.S.
South Korea 326030
SK Bioscience Co.,Ltd Logo
A global biotech firm developing vaccines for diseases like COVID-19, influenza, and shingles.
South Korea 302440

Talk to a Data Expert

Have a question? We'll get back to you promptly.